Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Alliance Foundation Trials, LLC.
- Study ID
- NCT06963723
- Status
- Recruiting
Conditions
- Advanced Cancer
- Metastatic Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 21 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Financial Hardship Screening — OTHERFinancial Hardship Screening and Financial Needs Assessment
- Enhanced Usual Care — OTHEREnhanced Usual Care
Study Details
The study aims to determine whether monthly remote digital financial hardship screening among adults with advanced/metastatic cancer, undergoing outpatient systemic therapy with non-curative intent, improves patient-centered outcomes, including financial worry, health-related quality of life (HRQoL), symptom burden, patient-reported cancer treatment adherence, and exploratory outcomes of overall survival, patient-reported economic burden, patient-reported support received, patient-reported financial coping strategies, and health insurance literacy.
Key Dates
- Start date
- Jul 1, 2025
- Status verified
- May 2026
- Primary completion
- Oct 1, 2028
- Completion
- Apr 1, 2029
Study Design
- Enrollment
- 1,000 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- HEALTH_SERVICES_RESEARCH
Arms
- Experimental: InterventionParticipants randomized to the intervention arm will complete their monthly screening using the single-item screening question (every 4 weeks for 12 months).
- Active Comparator: Enhanced Usual CareParticipants randomized to receive enhanced usual care will not be systematically screened for financial hardship through the electronic PRO Core system.
Primary Outcome Measure
Financial Worry [ Time Frame: 6 months ]
Central Contacts
- AFT Quality Management Group Inbox617-732-8727
Locations (6)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Dignity Health | Phoenix | Arizona | 85004 | Vamsee Torri, MD |
| New Hampshire Oncology-Hematology, PA | Concord | New Hampshire | 03301 | - |
| Solinsky Center for Cancer Care | Manchester | New Hampshire | 03103 | - |
| New York City Health and Hospitals | New York | New York | 10004 | Debra Ferman, MD |
| Sanford Health | Fargo | North Dakota | 58102 | |
| Gibbs Cancer Center | Spartanburg | South Carolina | 29303 |
Find similar trials in Phoenix, AZ
Related Studies
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)PHASE1/PHASE2 · Recruiting · PMV Pharmaceuticals, Inc · Irvine, California
- A Study of ART0380 for the Treatment of Advanced or Metastatic Solid TumorsPHASE1/PHASE2 · Recruiting · Artios Pharma Ltd · Birmingham, Alabama
- Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid TumorsPHASE1 · Recruiting · I-Mab Biopharma US Limited · Orange, California
- A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor CancerPHASE1/PHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · New York, New York